JNCI Cancer Spectrum: Neighborhood-level Social Determinants of Health Burden among AYA Cancer Patients and Impact on Overall Survival (Aune)

July 29, 2024

 Elizabeth R Rodriguez, B.S, Tori Tonn, B.S, Midhat Jafry, B.S, Sairah Ahmed, M.D, Branko Cuglievan, M.D, J Andrew Livingston, M.D, Christopher R Flowers, M.D, Gregory J Aune, M.D., Ph.D, Karen H Albritton, M.D, Michael E Roth, M.D, Qian Xiao, Ph.D, Michelle A T Hildebrandt, Ph.D Abstract Purpose Neighborhood socioeconomic deprivation has been linked to adverse health outcomes. Yet, it is unclear if neighborhood-level social determinants [...]

Science Advances: IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes (Gupta Lab)

July 17, 2024

                   ZHIJUN QIU JIHANE KHALIFE,  PURUSHOTH ETHIRAJ CARINE JAAFAR,  AN-PING LIN,  KENNETH N. HOLDER,  JACOB P. RITTER,  LILLY CHIOU GABRIELA HUELGAS-MORALES SADIA ASLAM, ZHAO ZHANG ZHIJIE LIU SHAILEE ARYA,  YOGESH K. GUPTA PATRICIA L. M. DAHIA RICARDO C.T. AGUIAR Abstract The mechanism by which interferon regulatory factor 8 (IRF8) mutation contributes to [...]

MDPI Cells: Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy (Bishop Lab)

July 15, 2024

 Qiwei Yang Obianuju Sandra Madueke-Laveaux Han Cun Marta Wlodarczyk Natalia Garcia Katia Candido Carvalho Ayman Al-Hendy Abstract Uterine leiomyosarcoma (uLMS) is the most common subtype of uterine sarcomas. They have a poor prognosis with high rates of recurrence and metastasis. The five-year survival for uLMS patients is between 25 and 76%, with survival rates approaching [...]

JCO Precision Oncology: Disparate Rates of Germline Variants in Cancer Predisposition Genes in African American/Black Compared With Non-Hispanic White Individuals Between 2015 and 2022 (Tomlinson)

July 12, 2024

 Rachel B. Wyatt Castillo, MS, CGC, Sarah M. Nielsen, MS, CGC, Elaine Chen, PhD, Brandie Heald, MS, CGC,, Rachel E. Ellsworth, PhD  Edward D. Esplin, MD, PhD, FACMG, and Gail E. Tomlinson, MD, PhD  Abstract Purpose African American/Black (AA/B) individuals are under-represented in genomic databases and thus less likely to receive definitive information from germline genetic testing (GGT) than non-Hispanic White (NHW) individuals. With nearly 500,000 AA/B and [...]

eLife: SERBP1 interacts with PARP1 and is Present in PARylation-Dependent Protein Complexes Regulating Splicing, Cell Division, and Ribosome Biogenesis (Penalva, Libich, et al)

July 3, 2024

 Kira Breunig Xiufen Lei Mauro Montalbano Gabriela D. A. Guardia Shiva Ostadrahimi Victoria Alers Adam Kosti Jennifer Chiou Nicole Klein Corina Vinarov Lily Wang Mujia Li Weidan Song W. Lee Kraus David S. Libich Stefano Tiziani Susan T. Weintraub Pedro A. F. Galante Luiz O. F. Penalva Abstract RNA binding proteins (RBPs) containing intrinsically disordered [...]

Scientific Reports: STEAP2 promotes hepatocellular carcinoma progression via increased copper levels and stress-activated MAP kinase activity (Chen)

June 20, 2024

 Carla Zeballos Torrez, Acarizia Easley, Hakim Bouamar, Guixi Zheng, Xiang Gu, Junhua Yang, Yu-Chiao Chiu, Yidong Chen, Glenn A. Halff, Francisco G. Cigarroa Lu-Zhe Sun Abstract Six Transmembrane Epithelial Antigen of Prostate 2 (STEAP2) belong to a family of metalloreductases, which indirectly aid in the uptake of iron and copper ions. Its role in hepatocellular [...]

Neoplasia: Aurkin-A, a TPX2-aurora a small molecule inhibitor, disrupts Alisertib-induced polyploidy in aggressive diffuse large B cell lymphoma. (Sung Lab)

June 18, 2024

 Patrick J Conway 1, Bárbara De La Peña Avalos 2, Jonathan Dao 3, Sebastian Montagnino 4, Dmytro Kovalskyy 2, Eloise Dray 5, Daruka Mahadevan 6 Abstract Chemotherapy-induced polyploidy is a mechanism of inherited drug resistance resulting in an aggressive disease course in cancer patients. Alisertib, an Aurora Kinase A (AK-A) ATP site inhibitor, induces cell cycle disruption resulting in polyaneuploidy in Diffuse Large B Cell Lymphoma (DLBCL). Propidium [...]

Cell Death & Disease: Impact of the thyroid hormone T3 and its nuclear receptor TRα1 on colon cancer stem cell phenotypes and response to chemotherapies (Penalva)

May 2, 2024

 Maria Virginia Giolito, Serguei Bodoirat, Theo La Rosa, Mathieu Reslinger, Gabriela D. A. Guardia, Jana Mourtada, Leo Claret, Alain Joung, Pedro A. F. Galante, Luiz O. F. Penalva & Michelina Plateroti Abstract Colorectal cancers (CRCs) are highly heterogeneous and show a hierarchical organization, with cancer stem cells (CSCs) responsible for tumor development, maintenance, and drug resistance. [...]

Current Protocols: Approaches for Mapping and Analysis of R-loops (Bishop Lab)

April 29, 2024

 Pramiti Mukhopadhyay, Henry Miller, Aiola Stoja, Alexander J. R. Bishop Abstract R-loops are nucleic acid structures composed of a DNA: RNA hybrid with a displaced non-template single-stranded DNA. Current approaches to identify and map R-loop formation across the genome employ either an antibody targeted against R-loops (S9.6) or a catalytically inactivated form of RNase H1 (dRNH1), a nuclease [...]

Patterns: Predicting drug response through tumor deconvolution by cancer cell lines (Chen Lab)

April 23, 2024

 Yu-Ching Hsu 1 2 3 4, Yu-Chiao Chiu 5 6, Tzu-Pin Lu 3, Tzu-Hung Hsiao 7, Yidong Chen 4 8 9 Highlights •Scaden-CA is a deep-learning model for tumor deconvolution •Tumor deconvolution facilitates the use of a drug response prediction algorithm •The model explores drug response mechanisms via DNA mutations and/or expression changes The bigger picture Drug repurposing involves utilizing approved or investigational drugs beyond the scope of the original medical application. This approach offers [...]